CVS Health Corporation – Consensus ‘buy’ rating and 22.6% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

CVS Health Corporation which can be found using ticker (CVS) have now 22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $104.00 and $74.00 calculating the mean target price we have $87.05. Now with the previous closing price of $71.02 this now indicates there is a potential upside of 22.6%. The 50 day moving average now sits at $69.43 and the 200 day moving average is $71.63. The total market capitalization for the company now stands at 94.59B. The stock price for the company is currently $73.50 USD

The potential market cap would be $115,936,516,992 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 11.26, revenue per share of $268.63 and a 3.64% return on assets.

CVS Health Corporation, together with its subsidiaries, is a diversified health solutions company. The Company’s segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Its Health Care Benefits offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and diagnostic testing.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search